Semigran Marc 4
4 · Edgewise Therapeutics, Inc. · Filed Jan 3, 2023
Insider Transaction Report
Form 4
Semigran Marc
Chief Development Officer
Transactions
- Award
Stock Option (Right to Buy)
2022-12-30+300,000→ 300,000 totalExercise: $8.94Exp: 2032-12-30→ Common Stock (300,000 underlying)
Footnotes (1)
- [F1]1/4th of the shares subject to the option become vested and exercisable on December 19, 2023 and 1/48th of the shares subject to the option continue to vest each month, subject to the Reporting Person continuing as a service provider through each vest date.